Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex, Optim to Establish Digital Medicine Joint Venture

NEW YORK – Japanese diagnostics device firm Sysmex and artificial intelligence company Optim said on Friday  that they have agreed to establish a joint venture aimed at the development and operation of services and platforms for digital medicine.

The two companies formed a business alliance this February and have been collaborating on initiatives to combine Sysmex’s global sales and service network with Optim’s artificial intelligence and data management technologies, including a product it calls Optim Cloud IoT OS. 

Under the newly agreed upon joint venture, the partners said that they plan to develop and test new diagnostic methods that combine image information from gene tests with AI analysis, as well as to use AI for image processing of various data obtained from existing Sysmex analyzers. 

The venture, which they plan to establish in January, will also seek collaborations with pharmaceutical companies, manufacturers of medical devices, and other companies, the firms said. Some discussions are already ongoing with potential pharma and device partners.

Financial terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.